Fortress Biotech(FBIO)
$1.91+-0.08 (+3.24%)
FBIO
Fortress Biotech financials statements
$1.91
At close:+-0.08 (+3.24%)
Want to see FBIO full AI Analyst Report?
Fortress Biotech (FBIO) Ratios
1,597 Followers
Fortress Biotech Ratios
FBIO's free cash flow for Q2 2026 was $-59.36M. For the 2026 fiscal year, FBIO's free cash flow was decreased by $-79.00K and operating cash flow was $-59.28M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.49 | 1.27 | 1.38 | 1.80 | 3.43 |
| Quick Ratio | 2.30 | 1.06 | 1.26 | 1.69 | 3.33 |
| Cash Ratio | 1.60 | 0.80 | 0.95 | 1.40 | 3.03 |
| Solvency Ratio | 0.09 | -0.28 | -0.33 | -0.32 | -0.34 |
| Operating Cash Flow Ratio | -1.32 | -1.12 | -1.51 | -1.40 | -1.15 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -128.31 | -13.56 | -17.62 | -21.90 |
| Net Current Asset Value | $ 476.00K | $ -55.50M | $ -48.92M | $ -13.84M | $ 175.84M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.40 | 0.53 | 0.53 | 0.43 | 0.19 |
| Debt-to-Equity Ratio | 1.49 | 3.34 | 3.93 | 3.05 | 0.69 |
| Debt-to-Capital Ratio | 0.60 | 0.77 | 0.80 | 0.75 | 0.41 |
| Long-Term Debt-to-Capital Ratio | 0.54 | 0.72 | 0.73 | 0.69 | 0.30 |
| Financial Leverage Ratio | 3.72 | 6.34 | 7.43 | 7.05 | 3.65 |
| Debt Service Coverage Ratio | -2.24 | -9.93 | -6.20 | -8.15 | -7.11 |
| Interest Coverage Ratio | -8.06 | -11.12 | -11.37 | -14.92 | -12.32 |
| Debt to Market Cap | 0.58 | 1.39 | 2.88 | 1.76 | 0.25 |
| Interest Debt Per Share | 2.98 | 4.13 | 12.47 | 23.80 | 16.58 |
| Net Debt to EBITDA | 0.25 | -0.18 | -0.06 | 0.26 | 1.58 |
| Profitability Margins | |||||
| Gross Profit Margin | 66.92% | 63.80% | 72.91% | 59.37% | 53.36% |
| EBIT Margin | -39.24% | -188.91% | -167.69% | -268.07% | -222.35% |
| EBITDA Margin | -31.88% | -181.17% | -160.59% | -255.73% | -212.48% |
| Operating Profit Margin | -111.00% | -191.38% | -168.43% | -268.76% | -274.08% |
| Pretax Profit Margin | -53.01% | -209.00% | -181.79% | -281.83% | -238.92% |
| Net Profit Margin | 10.77% | -79.75% | -71.75% | -114.30% | -94.06% |
| Continuous Operations Profit Margin | -52.03% | -209.54% | -182.40% | -282.42% | -239.60% |
| Net Income Per EBT | -20.32% | 38.16% | 39.47% | 40.56% | 39.37% |
| EBT Per EBIT | 47.76% | 109.21% | 107.93% | 104.86% | 87.17% |
| Return on Assets (ROA) | 3.67% | -31.89% | -36.20% | -29.42% | -16.32% |
| Return on Equity (ROE) | 13.66% | -202.30% | -268.97% | -207.51% | -59.54% |
| Return on Capital Employed (ROCE) | -51.71% | -151.57% | -172.29% | -122.20% | -63.81% |
| Return on Invested Capital (ROIC) | -49.97% | -145.10% | -154.60% | -113.59% | -62.25% |
| Return on Tangible Assets | 4.31% | -40.94% | -41.18% | -32.41% | -16.85% |
| Earnings Yield | 6.67% | -109.02% | -248.37% | -147.59% | -31.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.11 | 5.54 | 5.49 | 2.67 | 2.89 |
| Payables Turnover | 1.47 | 0.66 | 0.66 | 0.54 | 0.68 |
| Inventory Turnover | 2.17 | 1.45 | 2.24 | 2.17 | 3.25 |
| Fixed Asset Turnover | 4.27 | 3.37 | 3.60 | 2.29 | 2.02 |
| Asset Turnover | 0.34 | 0.40 | 0.50 | 0.26 | 0.17 |
| Working Capital Turnover Ratio | 1.36 | 2.26 | 1.25 | 0.44 | 0.30 |
| Cash Conversion Cycle | 92.26 | -234.94 | -325.82 | -374.40 | -301.15 |
| Days of Sales Outstanding | 172.75 | 65.83 | 66.46 | 136.60 | 126.23 |
| Days of Inventory Outstanding | 167.88 | 252.28 | 162.72 | 167.93 | 112.19 |
| Days of Payables Outstanding | 248.37 | 553.05 | 555.00 | 678.93 | 539.57 |
| Operating Cycle | 340.63 | 318.11 | 229.18 | 304.53 | 238.42 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.36 | -3.86 | -15.81 | -30.28 | -21.40 |
| Free Cash Flow Per Share | -2.36 | -4.58 | -16.81 | -30.79 | -24.40 |
| Dividend Paid and CapEx Coverage Ratio | -99.06 | -4.07 | -7.60 | -15.16 | -4.64 |
| Capital Expenditure Coverage Ratio | 0.00 | -5.35 | -15.83 | -58.72 | -7.13 |
| Operating Cash Flow Coverage Ratio | -0.89 | -1.06 | -1.45 | -1.41 | -1.55 |
| Operating Cash Flow to Sales Ratio | -1.04 | -1.39 | -1.52 | -2.37 | -1.69 |
| Free Cash Flow Yield | -64.41% | -225.62% | -558.38% | -311.05% | -65.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -54.30 | -0.75 | -0.40 | -0.68 | -3.16 |
| Price-to-Sales (P/S) Ratio | 1.61 | 0.73 | 0.29 | 0.77 | 2.97 |
| Price-to-Book (P/B) Ratio | 2.05 | 1.86 | 1.08 | 1.41 | 1.88 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.55 | -0.44 | -0.18 | -0.32 | -1.54 |
| Price-to-Operating Cash Flow Ratio | -1.55 | -0.53 | -0.19 | -0.33 | -1.75 |
| Price-to-Earnings Growth (PEG) Ratio | 0.56 | 0.01 | 0.01 | -0.03 | -0.15 |
| Enterprise Value Multiple | -4.81 | -0.58 | -0.24 | -0.04 | 0.18 |
| Enterprise Value | 97.04M | 60.89M | 32.08M | 7.74M | -26.50M |
| EV to EBITDA | -4.81 | -0.58 | -0.24 | -0.04 | 0.18 |
| EV to Sales | 1.53 | 1.06 | 0.38 | 0.10 | -0.39 |
| EV to Free Cash Flow | -1.48 | -0.64 | -0.24 | -0.04 | 0.20 |
| EV to Operating Cash Flow | -1.48 | -0.76 | -0.25 | -0.04 | 0.23 |
| Tangible Book Value Per Share | 1.24 | -1.61 | -2.31 | 3.85 | 39.16 |
| Shareholders’ Equity Per Share | 1.79 | 1.09 | 2.78 | 7.04 | 19.95 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.02 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 2.27 | 2.77 | 10.42 | 12.78 | 12.63 |
| Net Income Per Share | 0.24 | -2.21 | -7.48 | -14.61 | -11.88 |
| Tax Burden | -0.20 | 0.38 | 0.39 | 0.41 | 0.39 |
| Interest Burden | 1.35 | 1.11 | 1.08 | 1.05 | 1.07 |
| Research & Development to Revenue | 0.19 | 0.99 | 1.26 | 1.78 | 1.87 |
| SG&A to Revenue | 1.52 | 1.52 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.45 | 0.57 | 0.20 | 0.30 | 0.28 |
| Income Quality | 2.00 | 0.66 | 0.83 | 0.84 | 0.71 |
Currency in USD
